Skip to content
MarketScale
‹ Back to IndustriesSciences

The Hidden Roadblocks to Smarter Hospitals

As hospitals look to improve outcomes with faster, more informed decisions, infrastructure limitations remain a major hurdle. This episode—part two of a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring—dives into what’s holding back smarter, more connected care. Intel’s Andrew Lamkin, AI Solutions Architect, and Bikram Day,…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · Ai in HospitalsAndrew LamkinBikram DayClinical Data
Share

Key takeaways

01

As hospitals look to improve outcomes with faster, more informed decisions, infrastructure limitations remain a major hurdle.

02

This episode—part two of a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring—dives into what’s holding back smarter, more connected care.

03

Intel’s Andrew Lamkin, AI Solutions Architect, and Bikram Day,…

As hospitals look to improve outcomes with faster, more informed decisions, infrastructure limitations remain a major hurdle. This episode—part two of a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring—dives into what’s holding back smarter, more connected care. Intel’s Andrew Lamkin, AI Solutions Architect, and Bikram Day, Director of Informatics at Medical Informatics Corp., join Michelle Dawn Mooney to unpack the technical and clinical roadblocks buried deep in hospital systems today.

According to Day, the problem starts at the edge: “Most devices in the environment are not even connected. You end up with all that data going down a black hole.” Despite the availability of rich clinical data, fragmented device ecosystems and legacy workflows keep critical insights from reaching providers in time. Lamkin adds that while continuous monitoring has improved, infrastructure hasn’t kept pace with what’s possible: “Hospitals have networks and computing resources… we’re not talking about something that’s too high throughput to even start the conversation.”

The discussion emphasizes that many monitoring systems are still designed around outdated processes. “Almost all the infrastructure… has been there to replicate the manual charting,” Day explains. This manual-first mindset leads to hidden work for clinicians—connecting cables, hunting down data, and relying on telemetry stations that don’t scale. “We have way too many cables connecting things,” he says, but progress is happening with newer wireless sensors and shared protocols for devices like infusion pumps.

What’s needed to break through? Interoperability, automation, and rethinking the role of metadata. “Who, where, and when—all those factors are critical,” Day stresses, especially when preparing data for AI. Looking ahead, he calls for a mindset shift: “Use the human bandwidth for what the human is really good at… let the machines do their thing, which is crunching a whole bunch of data.”

Learn more about patient monitoring innovation by connecting with Andrew Lamkin and Bikram Day on LinkedIn, or by visiting Medical Informatics Corp. and Intel Health and Life Sciences.

Subscribe to this channel on Apple Podcasts and Spotify to hear more from the Intel Network and Edge Solutions Group.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512